Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice
Sujatha Iyengar1, David Schwartz2
1Jurist Center for Research, Hackensack University Medical Center, Hackensack, NJ, U.S.A.
Background/Aim:
Inositol trispyrophosphate (ITPP), reported to cure hepatomas in a preclinical rat model and to have beneficial effects in several other solid tumor models, is currently in clinical trial for liver cancer. We investigated whether aggressive glioblastomas could be effectively treated with ITPP alone or in combination with radiation therapy (RT).
Materials And Methods:
C57Bl/6 mice were intracranially injected with syngeneic GL261 glioblastoma cells and treated with hypofractionated radiation (5 Gy × 3), ITPP, or both. Tumors were followed by imaging, and mice sacrificed due to morbidity or at 90 days, with microscopic examination of brain sections.
Results:
RT alone significantly prolonged survival, whereas ITPP alone did not. Surprisingly, ITPP appeared to reduce the effectiveness of RT when added in combination.
Conclusion:
ITPP was ineffective as monotherapy for glioblastoma and appeared to interfere with the beneficial impact of RT.
Insights
Inositol trispyrophosphate (ITPP) did not effectively treat glioblastomas in mice. Combining ITPP with radiation therapy (RT) reduced RT’s survival benefits, indicating potential interference.
Area of Science:
- Oncology
- Preclinical Cancer Research
- Glioblastoma Therapeutics
Background:
- Inositol trispyrophosphate (ITPP) has shown promise in preclinical models for hepatomas and other solid tumors.
- ITPP is currently undergoing clinical trials for liver cancer treatment.
- The efficacy of ITPP against aggressive glioblastomas remains unexplored.
Purpose of the Study:
- To evaluate the effectiveness of inositol trispyrophosphate (ITPP) as a monotherapy for glioblastoma.
- To assess the combined effect of ITPP and radiation therapy (RT) in treating glioblastoma.
- To determine if ITPP enhances or interferes with RT in glioblastoma models.
Main Methods:
- Syngeneic GL261 glioblastoma cells were implanted intracranially in C57Bl/6 mice.
- Mice were treated with hypofractionated radiation therapy (5 Gy × 3), ITPP, or a combination of both.
- Tumor progression was monitored via imaging, and survival analysis was performed.
Main Results:
- Radiation therapy (RT) alone significantly prolonged survival in glioblastoma-bearing mice.
- Inositol trispyrophosphate (ITPP) monotherapy did not improve survival.
- The combination of ITPP and RT showed a reduced survival benefit compared to RT alone, suggesting interference.
Conclusions:
- ITPP is ineffective as a standalone treatment for glioblastoma in this preclinical model.
- ITPP may interfere with the therapeutic efficacy of radiation therapy in glioblastoma treatment.
- Further investigation is needed to understand the interaction between ITPP and RT.
